Tumor molecular age acceleration is associated with early progression in diffuse large B-cell lymphoma
Tumor molecular age acceleration is associated with early progression in diffuse large B-cell lymphoma
This study identifies a molecular aging signature that predicts early disease progression, providing a potential biomarker for risk stratification in DLBCL patients treated with R-CHOP.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024)
- Mantle‑Cell Lymphoma (MCL)
- Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)
- Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report
- Loncastuximab in high‑risk and heavily pre‑treated relapsed/refractory diffuse large B‑cell lymphoma: a real‑world analysis from 21 US centers